Table 4.
Multivariate analyses for recurrence-free and overall survival in patients with clinical stage I NSCLC
| RFS | OS | |||
|---|---|---|---|---|
| Variables | HR (95% CI) | P value | HR (95% CI) | P value |
| Age at operation, y | ||||
| < 70 | 1 | |||
| ≥ 70 | – | – | 2.39 (1.09–5.24) | 0.029 |
| Serum CEA, ng/ml | ||||
| ≤ 5 | 1 | 1 | ||
| > 5 | 1.03 (0.98–1.05) | 0.061 | 1.74 (0.79–3.81) | 0.163 |
| SUVmax of primary tumor | ||||
| ≤ 2.3 | 1 | 1 | ||
| > 2.3 | 3.78 (1.61–8.72) | 0.002 | 3.43 (1.36–8.61) | 0.008 |
| D-dimer, μg/ml | ||||
| ≤ 1.0 | 1 | 1 | ||
| > 1.0 | 1.92 (1.33–2.91) | 0.041 | 2.24 (1.05–4.69) | 0.032 |
| Pleural invasion | ||||
| Absent | 1 | |||
| Present | 1.05 (0.98–1.09) | 0.071 | – | – |
| Pathological stage | ||||
| Stage I | 1 | 1 | ||
| Stage II/III | 4.01 (1.64–9.91) | 0.003 | 4.11 (1.65–9.98) | 0.003 |
NSCLC non-small cell lung cancer, CEA carcinoembryonic antigen, SUV max maximum standardized uptake value, RFS recurrence-free survival, OS overall survival, HR hazard ratio, CI confidence interval